36.80

0.78% -0.29

After Hours: 36.80

Crinetics Pharmaceuticals Inc (CRNX)

Overview News Price History Option Chain Financials Why CRNX Down? Discussions Forecast

Crinetics Pharmaceuticals Inc stock is traded at $36.80, with a volume of 702.43K. It is down -0.78% in the last 24 hours and down -5.88% over the past month. Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Previous Close:

$37.09

Open:

$37.215

24h Volume:

702.43K

Relative Volume:

0.60

Market Cap:

$3.88B

Revenue:

$18.07M

Net Income/Loss:

$-496.39M

P/E Ratio:

-7.1689

EPS:

-5.1333

Net Cash Flow:

$-419.52M

1W Performance:

+0.08%

1M Performance:

-5.88%

6M Performance:

-14.14%

1Y Performance:

+22.22%

1-Day Range:

$36.64

$37.80

1-Week Range:

$33.89

$37.80

52-Week Range:

$25.83

$57.99

Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile

Name

Crinetics Pharmaceuticals Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

858-450-6464

Address

6055 LUSK BLVD., SAN DIEGO, CA

Employee

594

Twitter

@Crinetics

Next Earnings Date

2026-05-07

Latest SEC Filings

CRNX's Discussions on Twitter

Compare CRNX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRNX Crinetics Pharmaceuticals Inc	36.80	3.91B	18.07M	-496.39M	-419.52M	-5.1333
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-12-26	Upgrade	Goldman	Neutral → Buy
Jul-10-25	Initiated	Goldman	Neutral
Mar-25-25	Initiated	Stifel	Buy
Feb-11-25	Initiated	TD Cowen	Buy
Feb-04-25	Initiated	Wolfe Research	Peer Perform
Jan-22-25	Upgrade	Jefferies	Hold → Buy
Mar-06-24	Initiated	Citigroup	Buy
Jan-16-24	Initiated	Morgan Stanley	Overweight
Dec-21-23	Initiated	Jefferies	Hold
Nov-20-23	Resumed	JP Morgan	Overweight
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Aug-31-23	Initiated	Oppenheimer	Outperform
Apr-24-23	Initiated	Piper Sandler	Overweight
Mar-30-23	Initiated	Robert W. Baird	Outperform
Nov-30-21	Initiated	JMP Securities	Mkt Outperform
Nov-23-21	Initiated	Evercore ISI	Outperform
Jun-18-21	Upgrade	JP Morgan	Neutral → Overweight
Dec-23-19	Initiated	ROTH Capital	Buy
Feb-14-19	Initiated	H.C. Wainwright	Buy
Aug-13-18	Initiated	JP Morgan	Neutral
Aug-13-18	Initiated	Leerink Partners	Outperform
Aug-13-18	Initiated	Piper Jaffray	Overweight

View All

Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News

May 22, 2026

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026 - Yahoo Finance UK

May 22, 2026

CRNX Stock Price, Quote & Chart | CRINETICS PHARMACEUTICALS IN (NASDAQ:CRNX) - ChartMill

May 22, 2026

May 18, 2026

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? - The Motley Fool

May 18, 2026

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

May 18, 2026

Crinetics shares jump on robust PALSONIFY uptake and encouraging trial results - MSN

May 17, 2026

May 16, 2026

Precision Trading with Crinetics Pharmaceuticals Inc. (CRNX) Risk Zones - Stock Traders Daily

May 16, 2026

May 15, 2026

CRNX Maintained by Evercore ISI Group -- Price Target Lowered to $88 - GuruFocus

May 15, 2026

T. Rowe Price (NASDAQ: CRNX) reports 5.1% holding in Crinetics - Stock Titan

May 15, 2026

Wellington Management Group (CRNX) reports 7.79% beneficial stake in Crinetics - Stock Titan

May 15, 2026

Driehaus reduces holding in Crinetics Pharmaceuticals (NASDAQ: CRNX) to 6.11% - Stock Titan

May 15, 2026

Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Q1 2026 Revenue Growth And Wider Net Loss - Sahm

May 15, 2026

May 13, 2026

Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11% - Yahoo Finance

May 13, 2026

May 12, 2026

Crinetics Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:CRNX) 2026-05-12 - Seeking Alpha

May 12, 2026

Crinetics outlines plan to exceed 75% Palsonify coverage by end of Q3 2026 while funding operations into 2030 - MSN

May 12, 2026

Twilio To Rally Over 25%? Here Are 10 Top Analyst Forecasts For Monday - Sahm

May 12, 2026

What is HC Wainwright's Estimate for CRNX Q2 Earnings? - MarketBeat

May 12, 2026

Lifesci Capital Has Bullish Estimate for CRNX Q2 Earnings - MarketBeat

May 12, 2026

May 11, 2026

Earnings call transcript: Crinetics Pharma Q1 2026 revenue beats forecast - Investing.com India

May 11, 2026

Earnings call transcript: Crinetics Pharma Q1 2026 revenue beats forecast By Investing.com - Investing.com Nigeria

May 11, 2026

CRNX Maintained by Oppenheimer -- Price Target Lowered to $84.00 - GuruFocus

May 11, 2026

Oppenheimer Cuts Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $84.00 - MarketBeat

May 11, 2026

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance

May 11, 2026

Oppenheimer Adjusts Crinetics Pharmaceuticals PT to $84 From $87, Maintains Outperform Rating - marketscreener.com

May 11, 2026

Oppenheimer cuts Crinetics stock price target on revenue beat By Investing.com - Investing.com Canada

May 11, 2026

HC Wainwright Has Negative Estimate for CRNX FY2030 Earnings - MarketBeat

May 11, 2026

May 09, 2026

Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Momentum - Yahoo Finance

May 09, 2026

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2026 Earnings Call Transcript - Insider Monkey

May 09, 2026

Crinetics Pharmaceuticals (NASDAQ:CRNX) Lowered to "Strong Sell" Rating by Wall Street Zen - MarketBeat

May 09, 2026

Crinetics Pharmaceuticals (CRNX) Cash Burn And EPS Loss Reinforce Bearish Profitability Concerns - Sahm

May 09, 2026

Crinetics Q1 2026 slides: Palsonify launch drives 26% revenue beat By Investing.com - Investing.com South Africa

May 09, 2026

May 08, 2026

Crinetics (CRNX) Q1 2026 Earnings Transcript - AOL.com

May 08, 2026

Crinetics Pharmaceuticals Down Over 14%, on Pace for Largest Percent Decrease Since January 2025 -- Data Talk - Moomoo

May 08, 2026

CRNX Maintained by Citizens -- Price Target Lowered to $95.00 - GuruFocus

May 08, 2026